Chemical synthesis of galantamine, an acetylcholinesterase inhibitor for treatment of Alzheimer’s disease

Author： Marco-Contelles José   Rodríguez Carolina   García Antonio G  

Publisher： Informa Healthcare

ISSN： 1354-3776

Source： Expert Opinion on Therapeutic Patents, Vol.15, Iss.5, 2005-05, pp. : 575-587

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Review of Clinical Pharmacokinetics and Pharmacodynamics of Galantamine, a Reversible Acetylcholinesterase Inhibitor for the Treatment of Alzheimer 's Disease, in Healthy Subjects and Patients

By  

Current Clinical Pharmacology, Vol. 5, Iss. 2, 2010-05 ,pp. : 115-124

Bentham Science Publishers

Access to resources Recommend Favorite

Acetylcholinesterase inhibitors in the treatment of Alzheimer’s disease

By Gauthier S.  

Expert Opinion on Investigational Drugs, Vol. 8, Iss. 10, 1999-10 ,pp. : 1511-1520

Informa Healthcare

Access to resources Recommend Favorite

A Long-Term Comparison of Galantamine and Donepezil in the Treatment of Alzheimer’s Disease

By Wilcock G.  

Drugs & Aging, Vol. 20, Iss. 10, 2003-01 ,pp. : 777-789

Adis International

Access to resources Recommend Favorite

Current status and new developments with galantamine in the treatment of Alzheimer’s disease

By Tariot Pierre  

Expert Opinion on Pharmacotherapy, Vol. 2, Iss. 12, 2001-12 ,pp. : 2027-2049

Informa Healthcare

Access to resources Recommend Favorite

Galantamine in the Treatment of Cognitive Decline in Patients with Vascular Dementia or Alzheimer’s Disease with Cerebrovascular Disease

By Small G.  

CNS Drugs, Vol. 17, Iss. 12, 2003-01 ,pp. : 905-914

Adis International

Access to resources Recommend Favorite